RTI Biologics' BioCleanse allografts show positive clinical results RTI Biologics announced results of a recent randomized prospective clinical study of BioCleanse-processed bone-patellar tendon-bone allografts used in anterior cruciate ligament reconstruction surgery. The study compares the clinical outcomes of BTB allografts processed using RTIís patented BioCleanse Tissue Sterilization Process with a control group consisting of aseptically-processed allografts from the three U.S. tissue banks that provide this type of allograft. Results indicate that the sterilization process, BioCleanse, did not demonstrate a statistical difference in clinical outcomes for the BTB allograft at two years. The BioCleanse process may provide surgeons with allografts clinically similar to aseptically-processed allograft tissue with the benefit of addressing donor-to-recipient disease.
News For RTIX From The Last 14 Days
Check below for free stories on RTIX the last two weeks.
RTI Surgical reports Q1 EPS ex-items (1c), consensus (1c) Reports Q2 revenue $60.7M, consensus $55.43M. The company said, "Our Q1 results exceeded our expectations and represent another sign of progress as we return the company to growth. We continue to see solid recovery in our direct spine and direct sports businesses."